Nexstim’s proprietary navigated transcranial magnetic stimulation (TMS) technology is at the core of its strategic review. Its accuracy, reliability, and reproducible effects are the key advantages and differentiating features vs the competition. These enable it to carve out a niche as a personalised and effective therapy (NBT) and diagnostic (NBS) for challenging brain disease and disorders. Nexstim’s proposed €2.2m rights issue will strength its balance sheet and provide the resources to continue to support its existing NBS and NBT businesses, and invest in pilot studies to explore potentially highly lucrative new opportunities in severe depression and chronic neuropathic pain. The COVID-19 pandemic has prompted cost saving measures, although Nexstim’s business remains resilient with a solid NBS installed base, flexible pricing models, and opportunities within NBT. Our Nexstim valuation is €31.2m (€0.50/share) valuation.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Hitting the right spot
Nexstim’s proprietary navigated transcranial magnetic stimulation (TMS) technology is at the core of its strategic review. Its accuracy, reliability, and reproducible effects are the key advantages and differentiating features vs the competition. These enable it to carve out a niche as a personalised and effective therapy (NBT) and diagnostic (NBS) for challenging brain disease and disorders. Nexstim’s proposed €2.2m rights issue will strength its balance sheet and provide the resources to continue to support its existing NBS and NBT businesses, and invest in pilot studies to explore potentially highly lucrative new opportunities in severe depression and chronic neuropathic pain. The COVID-19 pandemic has prompted cost saving measures, although Nexstim’s business remains resilient with a solid NBS installed base, flexible pricing models, and opportunities within NBT. Our Nexstim valuation is €31.2m (€0.50/share) valuation.